MTS MEDICATION TECHNOLOGIES, INC /DE/ 4
4 · MTS MEDICATION TECHNOLOGIES, INC /DE/ · Filed Dec 22, 2009
Insider Transaction Report
Form 4
KAZARIAN DAVID W
Director
Transactions
- Disposition to Issuer
Common Stock
2009-12-22−1,250→ 0 total(indirect: By Spouse) - Disposition to Issuer
Common Stock
2009-12-22−25,586→ 0 total - Disposition to Issuer
Options (right to buy)
2009-12-22−2,400→ 0 totalExercise: $2.50From: 2000-03-31Exp: 2010-03-31→ Common Stock (24,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−3,000→ 0 totalExercise: $2.67From: 2003-03-31Exp: 2013-03-31→ Common Stock (3,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−12,000→ 0 totalExercise: $1.50From: 2001-04-01Exp: 2011-04-01→ Common Stock (12,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−3,000→ 0 totalExercise: $2.50From: 2002-04-01Exp: 2012-04-01→ Common Stock (3,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−3,000→ 0 totalExercise: $12.45From: 2004-03-31Exp: 2014-03-31→ Common Stock (3,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−6,000→ 0 totalExercise: $7.03From: 2006-08-25Exp: 2016-08-25→ Common Stock (6,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−5,000→ 0 totalExercise: $5.85From: 2009-07-02Exp: 2018-07-02→ Common Stock (5,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger, dated as of August 7, 2009 ("Merger Agreement"), by and among the Issuer, MedPak Holdings, Inc., a Delaware corporation ("Parent"), and MedPak Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), whereby Merger Sub merged with and into the Issuer (the "Merger"). The reporting person's shares were exchanged for cash consideration of $5.75 per share (the "Merger Consideration"). The Merger was approved by the stockholders of the Issuer of December 18, 2009 and became effective on December 22, 2009.
- [F2]The options were cancelled and terminated by the Issuer's Board of Directors in accordance with the Merger Agreement. The reporting person received, with respect to any shares of the Issuer's common stock issuable under a stock option, an amount equal to the excess, if any, of (i) the Merger Consideration per share over (ii) the exercise price per share payable with respect of such shares of the Issuer's common stock issuable under such stock option.